Drug reference
etidronate
Bisphosphonate · Antiresorptive agent
BisphosphonateAntiresorptive agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Not yet extracted
Indications
Paget diseaseheterotopic ossificationhypercalcemiaHypercalcaemiaPaget’s diseaseHumoral Hypercalcemia of Malignancy
Dosing
- Adult
- 5–7.5 mg/kg/day
Pharmacokinetics
Bioavailability
6%
Contraindications
- abnormalities that delay esophageal emptying
- Gastroesophageal reflux
- Peptic ulcer
- Renal impairment (general BPN contraindications)
Side effects
Common
heartburnesophageal irritationesophagitisabdominal paindiarrheaGastric irritation
Serious
- nephrotoxicity
- osteonecrosis of the jaw
- esophageal ulcers
- esophageal erosions
- Osteomalacia (with continuous therapy)
Related guidelines
Other Bisphosphonate drugs
Ask House about etidronate
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e, Goodman & Gilman 14e, Harrison 22e·Updated: 2026-05-10